Home

Moshe Arkin

CIK 1321178 · Vice Chairman · last filed 2026-08-24

Moshe Arkin is a Vice Chairman who has filed 88 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider bought $3.6M of ODYS on Aug 24, 2026. Across all open-market trades the lifetime net is −$259.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $98.2M across reported positions. 14 SEC filings were submitted jointly with M. ARKIN (1999) LTD.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$98.19M

Companies

5

Total Filings

88

Lifetime Open-Market Net

-$259.64M

Filer Profile

Reported Address
6 HACHOSHLIM ST.
HERZELIA
Related Filers
M. ARKIN (1999) LTD. — 14 joint filings, latest 2011-08-12
U.M. AccelMed, Limited Partnership — 3 joint filings, latest 2010-06-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ODYS Director 2,624,838 $3.45 $9.06M $3.60M 2 2026-08-24
HOWL 10%+ Owner 1,235,917 $0.98 $1.21M $19.20M 1 2021-05-04
KROS 10%+ Owner 1,725,565 $11.08 $19.12M $5.76M 1 2020-04-13
PRGO Director 5,036,958 $13.66 $68.80M -$285.73M 80 2011-09-02
Orexigen Therapeutics, Inc. (OREX) Delisted 460,965 — — -$2.47M 1 2010-08-16

Recent Filings

88 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-24 ODYS Buy (P) +1,125,000 $3.60M EDGAR
2026-03-27 ODYS Mixed +271,897 $1.50M EDGAR
2021-05-04 HOWL Mixed +6,139,902 $19.20M EDGAR
2020-04-13 KROS Mixed +6,039,306 $5.76M EDGAR
2011-09-02 PRGO Sell (S) −79,855 -$7.65M EDGAR
2011-09-01 PRGO Sell (S) −170,145 -$16.41M EDGAR
2011-05-24 PRGO Sell (S) −400 -$34.8K EDGAR
2011-05-20 PRGO Sell (S) −180,362 -$15.59M EDGAR
2011-05-16 PRGO Sell (S) −107,195 -$9.37M EDGAR
2011-05-12 PRGO Sell (S) −128,728 -$11.25M EDGAR
Showing 1–10 of 88
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.